STAT

JANUARY 31, 2024

… Novo Nordisk has begun to increase availability of its blockbuster obesity drug Wegovy for new patients in the U.S. Overall, Novo saw 154% growth in obesity drug revenue in 2023, driven by sales of its older obesity drug Saxenda and the launch of Wegovy in additional countries.

Diabetes 266

Diabetes 266

STAT

APRIL 25, 2024

Senate Committee on Health, Education, Labor and Pensions is investigating the prices Novo Nordisk charges for its blockbuster medications, Ozempic and Wegovy, which are highly effective at treating diabetes and obesity but carry steep price tags, The New York Times writes. Bernie Sanders (I-Vt.), Bernie Sanders (I-Vt.), per package.

Packaging 259

Packaging Diabetes 259

Fuld & Company Blog

MARCH 27, 2023

W eight loss industr y stakeholders brace for a revolution as Wegovy , Ozempic and other semiglutide s pick up steam A new market is emerging thanks to the introduction of a highly effective weight loss solution in the form of a handy injectable pen. The only difference between Wegovy and Ozempic is the approved maintenance dose.

Diabetes 52

Diabetes Online Pharmacies Packaging Pharmaceutical Companies 52

Pharmaceutical Technology

JANUARY 17, 2023

Nonetheless, patients receiving the current standard of care, Novo Nordisk’s Wegovy (injectable semaglutide), are expected to self-administer treatment on a weekly basis. Despite its high price tag, bimagrumab’s unique features set it apart from currently marketed therapies.

Diabetes 52

Diabetes Hospitals 52

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. Wegovy has been associated with a 12.4% An immediate high demand for the drug and a shortage of Wegovy resulted in supply issues. compared to a 5.1%

Insurance Coverage and Processing 105

Insurance Coverage and Processing Diabetes Labelling Communication 105

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. Wegovy has been associated with a 12.4% An immediate high demand for the drug and a shortage of Wegovy resulted in supply issues. compared to a 5.1%

Insurance Coverage and Processing 98

Insurance Coverage and Processing Diabetes Labelling Communication 98